Saturday, September 10, 2022 5:07:39 PM
FDA cares about statistical endpoints. FDA has 6 efficacy endpoints they accept for approval consideration: Overall Survival, Disease-Free Survival (and Event-Free Survival), Objective Response Rate, Complete Response, Time to Progression and Progression-Free Survival, Time to Treatment Failure.
Read the FDA Guidance if you really would like to know:
https://www.fda.gov/media/71195/download
Even Dr. Liau does, as she is using PFS as the lead efficacy endpoint in her latest Keytruda/ATL combination trial.
Then there's the post hoc data dredged recurrent OS. The NWBO trial was a naïve GBM trial, but suddenly NWBO and the clinicians needed a new trial endpoint. So they ginned up a post hoc, data dredged recurrent GBM arm our of the air. Sample size only 64 patients. Bet the FDA will have something to say about a ginned up endpoint.
Read the FDA Guidance if you really would like to know:
https://www.fda.gov/media/71195/download
Even Dr. Liau does, as she is using PFS as the lead efficacy endpoint in her latest Keytruda/ATL combination trial.
Then there's the post hoc data dredged recurrent OS. The NWBO trial was a naïve GBM trial, but suddenly NWBO and the clinicians needed a new trial endpoint. So they ginned up a post hoc, data dredged recurrent GBM arm our of the air. Sample size only 64 patients. Bet the FDA will have something to say about a ginned up endpoint.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
